ESMO 2019 Significant overall survival improvement by the addition of abemaciclib to fulvestrant in pati... Read more
ESMO 2019 Half of the patients with metastatic melanoma treated with nivolumab-ipilimumab are still aliv... Read more
ASCO 2019 Ramucirumab plus erlotinib improves progression-free survival in EGFR-positive lung cancer Read more
ASCO 2019 FOLFOXIRI + bevacizumab shows progression-free survival benefit in mCRC patients with ≥3 bas... Read more
ASCO 2019 Pembrolizumab increases historic survival rate for certain people with advanced NSC lung cance... Read more
Top
